Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zoll Defibrillator Sales Growth, Upcoming Public AED Entry Buoy Stock In July

This article was originally published in The Gray Sheet

Executive Summary

Zoll Medical's upcoming entry into the public access automated external defibrillator (AED) market, coupled with revived sales growth in its third fiscal quarter, helped the firm's stock jump ahead 33% in July. The issue closed at $36.45, up $9 for the month.

You may also be interested in...

PMR Adverse Events, Elusive Efficacy Endpoints Cited In Panel Rejection

The reliance on hospitalization for angina as a safety endpoint in the clinical trials of CardioGenesis' Eclipse PMR (percutaneous myocardial revascularization) device masked the rate of significant adverse events related to the procedure, according to FDA's Circulatory System Devices Panel.

Zoll Banking On M-Series Superiority Claim In Entering Public AED Market

Zoll Medical is expecting the smaller size of its biphasic M-Series automated external defibrillator (AED) combined with FDA-cleared superiority claims over competing devices to result in a sizable chunk of the public access defibrillator market.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts